Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
224 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (2)

Medical Condition

  • Show all (59)
  • Autoimmune Disorders (2)
  • Blood Disorders (4)
  • Cancer (11)
    • (-) Gastrointestinal (1)
    • Gynecologic Cancer (4)
    • Kidney Cancer (1)
    • (-) Leukemia (2)
    • Skin Cancer (1)
    • Solid Tumors (1)
  • Diabetes (1)
  • Gastrointestinal and Digestive Diseases (2)
  • Healthy Volunteers (4)
  • Heart Disease (2)
  • Infectious Disease (4)
  • Neurological Disorders (6)
  • Nutrition (1)
  • Obstetrics & Gynecology (1)
  • Pediatrics (13)
  • Psychiatric Disorders (1)
  • Transplant (7)
Displaying 1 - 3 of 3

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that is used to…
Read More

Study of Combination Treatment to Reduce Occurrence and Severity of Chronic Graft Versus Host Disease (GVHD)

Condition: Cancer / Leukemia
Investigator: Monica Bhatia, MD
Status: Closed
The purpose of this study is to compare two different combinations of treatment plans to a standard transplant procedure in order to see whether one or both of them are better at reducing the occurrence and severity of chronic GVHD. The research portion of this study involves manipulation of your stem …
Read More

Study of Standard Chemotherapy Alone or Combined with Atezolizumab for Patients with Stage III Colon Cancer

Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body's immune system to more effectively kill cancer…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science